NEW YORK ─ Bio-Techne and Qiagen on Thursday announced the expansion and extension of a non-exclusive partnership to comarket exosome technology to biopharma companies and the joint development of new exosome-based products.
The agreement grants Hilden, Germany-based Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products. Following the agreement, both Bio-Techne and Qiagen will promote exosome technology to their respective global biopharma partners, Bio-Techne said in a statement. The initial phase of the comarketing agreement lasts 24 months, and there is potential to extend it further upon the fulfillment of certain conditions.
"Bio-Techne's exosome technology represents a novel diagnostic approach with broad applications that will be especially beneficial to our global pharma partners," Thierry Bernard, CEO of Qiagen, said in a statement.
The companies also announced the extension and expansion of an existing exclusive collaboration and license agreement that has been in place between Qiagen and Exosome Diagnostics, now part of Minneapolis-based Bio-Techne. The agreement includes the use of Exosome Diagnostics' platforms for biomarker discovery, the joint development of new products, and ongoing marketing activities to promote exosome technologies. The extended collaboration and joint product development agreement ends in 2028 and can be extended if agreed by both companies.
Financial and other terms of the agreements were not disclosed.